Bainbridge J W B, Mistry A, De Alwis M, Paleolog E, Baker A, Thrasher A J, Ali R R
Department of Molecular Genetics, Institute of Ophthalmology, University College London, London, UK.
Gene Ther. 2002 Mar;9(5):320-6. doi: 10.1038/sj.gt.3301680.
Retinal angiogenesis is a central feature of the leading causes of blindness. Current treatments for these conditions are of limited efficacy and cause significant adverse effects. In this study, we evaluated the angiostatic effect of gene transfer of the soluble VEGF receptor sFlt-1 in a mouse model of ischaemia-induced retinal neovascularisation using adenovirus and adeno-associated virus (AAV) vectors. We induced proliferative retinopathy in mice by exposure to 75% oxygen from postnatal day 7 (p7) to p12 and injected intravitreally recombinant viral vectors expressing the reporter green fluorescent protein (GFP) or vectors expressing the VEGF inhibitor sFlt-1. Efficient adenovirus-mediated GFP expression was evident in cells of the corneal endothelium and iris pigment epithelium. AAV-mediated GFP expression was evident in ganglion cells and cells of the inner nuclear layer of the retina. Vector-mediated sFlt-1 expression was confirmed by ELISA of pooled homogenised whole eyes. Injection of either vector expressing sFlt-1 resulted in a reduction in the number of neovascular endothelial cells by 56% and 52% for adenovirus and AAV vectors, respectively (P < 0.05). Local gene transfer of sFlt-1 consistently inhibits experimental retinal neovascularisation by approximately 50% and offers a powerful novel approach to the clinical management of retinal neovascular disorders.
视网膜血管生成是导致失明的主要病因的核心特征。目前针对这些病症的治疗效果有限且会引发显著的副作用。在本研究中,我们使用腺病毒和腺相关病毒(AAV)载体,在缺血诱导的视网膜新生血管形成的小鼠模型中评估了可溶性血管内皮生长因子受体sFlt-1基因转移的血管生成抑制作用。我们通过从出生后第7天(p7)至p12暴露于75%的氧气来诱导小鼠发生增殖性视网膜病变,并玻璃体内注射表达报告基因绿色荧光蛋白(GFP)的重组病毒载体或表达血管内皮生长因子抑制剂sFlt-1的载体。腺病毒介导的GFP高效表达在角膜内皮细胞和虹膜色素上皮细胞中明显可见。AAV介导的GFP表达在神经节细胞和视网膜内核层细胞中明显可见。通过对全眼球合并匀浆进行酶联免疫吸附测定(ELISA)证实了载体介导的sFlt-1表达。注射表达sFlt-1的任何一种载体,对于腺病毒和AAV载体,分别使新生血管内皮细胞数量减少了56%和52%(P < 0.05)。sFlt-1的局部基因转移持续抑制实验性视网膜新生血管形成约50%,并为视网膜新生血管疾病的临床治疗提供了一种强有力的新方法。